

SHORT REPORT

Open Access



Functional relevance of the multi-drug transporter *abcg2* on teriflunomide therapy in an animal model of multiple sclerosis

Lisa Thiele née Schrewe^{1,2*}, Kirsten Guse^{1,2}, Silvia Tietz¹, Jana Remlinger¹, Seray Demir², Xiomara Pedreiturria², Robert Hoepner¹, Anke Salmen¹, Maximilian Pistor^{1,2}, Timothy Turner³, Britta Engelhardt⁴, Dirk M. Hermann⁵, Fred Lühder⁶, Stefan Wiese⁷ and Andrew Chan^{1*}

Abstract

Background: The multi-drug resistance transporter ABCG2, a member of the ATP-binding cassette (ABC) transporter family, mediates the efflux of different immunotherapeutics used in multiple sclerosis (MS), e.g., teriflunomide (teri), cladribine, and mitoxantrone, across cell membranes and organelles. Hence, the modulation of ABCG2 activity could have potential therapeutic implications in MS. In this study, we aimed at investigating the functional impact of *abcg2* modulation on teri-induced effects in vitro and in vivo.

Methods: T cells from C57BL/6 J wild-type (wt) and *abcg2*-knockout (KO) mice were treated with teri at different concentrations with/without specific *abcg2*-inhibitors (Ko143; Fumitremorgin C) and analyzed for intracellular teri concentration (HPLC; LS-MS/MS), T cell apoptosis (annexin V/PI), and proliferation (CSFE). Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6J by active immunization with MOG_{35–55}/CFA. Teri (10 mg/kg body weight) was given orally once daily after individual disease onset. *abcg2*-mRNA expression (spinal cord, splenic T cells) was analyzed using qRT-PCR.

Results: In vitro, intracellular teri concentration in T cells was 2.5-fold higher in *abcg2*-KO mice than in wt mice. Teri-induced inhibition of T cell proliferation was two fold increased in *abcg2*-KO cells compared to wt cells. T cell apoptosis demonstrated analogous results with 3.1-fold increased apoptosis after pharmacological *abcg2*-inhibition in wt cells. *abcg2*-mRNA was differentially regulated during different phases of EAE within the central nervous system and peripheral organs. In vivo, at a dosage not efficacious in wt animals, teri treatment ameliorated clinical EAE in *abcg2*-KO mice which was accompanied by higher spinal cord tissue concentrations of teri.

Conclusion: Functional relevance of *abcg2* modulation on teri effects in vitro and in vivo warrants further investigation as a potential determinant of interindividual treatment response in MS, with potential implications for other immunotherapies.

Keywords: *abcg2*, Teriflunomide, Multiple sclerosis, Experimental autoimmune encephalomyelitis

* Correspondence: Lisa.Thiele@dbmr.unibe.ch; Andrew.Chan@insel.ch

¹Department of Neurology, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Freiburgstrasse, 3010 Bern, Switzerland

Full list of author information is available at the end of the article



Introduction

The ATP-binding cassette (ABC) transporter family is comprised of molecular transporters that use the energy of ATP hydrolysis to translocate various molecules across extra- and intracellular membranes in essential physiological processes, e.g., nutrient uptake, osmotic homeostasis, and protection from xenotoxins [1]. The transporter ABCG2 is highly expressed at physiological barriers like the intestinal epithelium, the blood-brain barrier (BBB), and hepatocytes. It binds a variety of approved pharmaceutical agents, contributing to their pharmacodynamics and kinetics [2, 3].

Different immunotherapeutics used for the treatment of multiple sclerosis (MS), i.e., teriflunomide (teri), mitoxantrone, and cladribine, are known substrates of ABCG2 [4–7]. Despite increasing treatment options in MS, unmet needs include potential predictors of therapeutic response and adverse drug reactions to possibly guide individualizing treatment strategies [8, 9].

Teri is an oral compound with presumed pleiotropic mechanisms of action. One prominent target appears to be selective inhibition of dihydro-orotate dehydrogenase (DHODH), a key mitochondrial enzyme in the de novo pyrimidine synthesis pathway, leading to a reduction in proliferation of activated T and B lymphocytes [10, 11]. Here, we investigated whether modulation of *abcg2* influences teri-induced effects in vitro in T cells and in vivo in experimental autoimmune encephalomyelitis (EAE).

Materials and methods

Ethics approval, animal studies, and human samples

Animal experiments were approved by the local authorities (Veterinary Office of the Canton of Bern, Switzerland, no. BE 64/16; North Rhine-Westphalia authorities for animal experimentation, no. 84-02.04.2015.A006). Wild-type (wt) C57BL/6J (Janvier, France) and *abcg2* knockout (*abcg2*-KO; St. Jude Children's Research Hospital, Memphis, TN [5];) mice (backcrossed to C57Bl/6 wt mice for > 10 generations) were used for in vivo (i.e., EAE) and in vitro studies. Mice were kept under standardized, pathogen-free conditions. Genotyping was performed with the KAPA Mouse Genotyping Kit (KAPA Biosystems, Woburn, USA); primer: *abcg2*-KO1 5'-AGG CGA CCT CTT CCA AGA CT-3', *abcg2*-KO2 5'-GCA GCG CAT CGC CTT CTA TC-3', WT1 5'-GTG CCA CCA TGT TCA ACT TA-3', WT2 5'-CTG CCA GAG TAG TGG AAG ATT-3' (Microsynth, Balgach, Switzerland). Human studies were approved by the local cantonal ethic committee Bern (KEK-BE 2017-00060), and CD3⁺ T cells were isolated from PBMCs of healthy donors.

Induction, teri treatment, and histopathology of EAE

Chronic EAE was induced by active immunization with 100 µg myelin-oligodendrocyte-glycoprotein peptide

35–55 (MOG_{35–55}) (Charité Berlin, Germany) in complete Freund's adjuvants (CFA) and disease severity was assessed clinically using a 10-point EAE scale: 0, normal; 1, reduced tone of tail; 2, limp tail, impaired righting; 3, absent righting; 4, gait ataxia; 5, mild paraparesis of hind limbs; 6, moderate paraparesis; 7, severe paraparesis or paraplegia; 8, tetraparesis; 9, moribund; 10, death [12]. Teri (provided by Sanofi Genzyme, Cambridge, USA) was dissolved in 25 mM Tris buffer (80 %) in H₂O (20%) at a pH of 7.5. After individual disease onset (score > 1), mice were treated with teri (10 mg/kg once daily, oral gavage [13, 14];) or respective vehicle for 17–20 consecutive days. Spinal cord tissue was embedded in paraffin and stained with hematoxylin and eosin (H&E) or luxol fast blue (LFB). Immunohistochemistry was performed for CD3⁺ T cells (rat- α -human CD3, 1:100, AbD Serotec, Düsseldorf, Germany), Mac3⁺ macrophages (rat- α -mouse Mac3, 1:100; BD Pharmingen, Heidelberg, Germany), and B220/CD45R⁺ B cells (rat- α -mouse CD45R, 1:200, AbD Serotec). Images were captured with a slide scanner (Pannoramic 250 Flash III, 3DHISTECH, Budapest, Hungary), and the inflammatory score (0, no inflammation; 1, cellular infiltration only in the perivascular areas and meninges; 2, mild cellular infiltration; 3, moderate cellular infiltration [15] or the demyelinated area (ratio of demyelinated area/total area) or number of immune cells within lesions was determined using CaseViewer (3DHISTECH). All in vivo experiments and histological analyses were performed in a blinded setup for the treatment group and genotype of animals.

FACS analysis of splenic and inguinal lymph node lymphocytes

Lymphocytes from PBS perfused mice suffering from EAE (at day 4 ± 1 after initiation of therapy) or healthy mice were isolated using a Wheaton homogenizer. Subsequently, cells were filtered through a 100-µm nylon mesh and washed (HBSS supplemented with 25 mM HEPES and 5% calf serum), and erythrocytes in splenic samples were lysed. For in vitro teri treatment of splenocytes from healthy mice, cells were incubated with 100 µM teri/DMSO or respective vehicle for 2 h at 37 °C in 5 mL medium (RPMI (Gibco) supplemented with 10% FBS, 2% L-glutamine (Gibco), 1% NEAA (Gibco), 1% sodium pyruvate (Gibco), 1% PenStrep (Gibco), and 0.05 mM β -mercaptoethanol (Merck)). In vitro-treated cells or cells from in vivo-treated mice were stimulated with 50 ng/mL phorbol myristate acetate (PMA; Alexis Biochemicals), 1 mg/mL ionomycin (BioVision, Inc.), and 3.3 µl/5 mL GolgiStop (BD Biosciences) for 4 h at 37 °C in 5 mL medium. After stimulation, cells were collected and stained for CD4, CD25, and FoxP3 using the Treg Detection Kit according to manufacturer's protocol (Myltenyi) or for intracellular cytokines (IFN- γ , IL-17,

GM-CSF, IL-4, IL-10) and surface markers (CD45, CD4, CD8) as adapted from [16]. For surface staining, cells were incubated with primary antibody (Additional file 6: Table S1) mixes in FACS buffer (DPBS, 2.5% FBS, and 0.1% NaN₃) for 30 min on ice. After a washing step, cells were fixed and permeabilized for 20 min on ice (BD Biosciences; Cytofix/CytopermTM). Cells were washed and incubated for intracellular staining with primary antibody (Additional file 6: Table S1) mixes in Perm/WashTM solution (BD Biosciences) for 30 min on ice. Cells were washed twice after the staining and resuspended in FACS buffer. Flow cytometry was performed using an Attune NxT flow cytometer (ThermoFisher scientific). Data analysis was performed with FlowJo software.

Isolation of murine and human T cells and flow cytometry analyses

Isolation of splenic T cells of healthy mice was performed using the Pan T Cell Isolation Kit II according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). Activated T cells (anti-murine-CD3, 10 µg/mL + anti-murine-CD28, 10 ng/mL; 5% CO₂, 37 °C [17]); were treated with teri (12.5–100 µM/DMSO, final concentration 0.1%) or DMSO (final concentration 0.1%) as control [18]. After 48 h of incubation, cell proliferation was quantified using the CellTraceTM CFSE (carboxy-fluorescein diacetat-succinimidylester) Cell Proliferation Kit according to the manufacturer's protocol (Invitrogen, Karlsruhe, Germany; flow cytometry) (Additional file 5: Figure S5A). For pharmacological *abcg2* inhibition in wt cells, Fumitremorgin C (FTC, 10 µM) or Ko143 (10 µM) were used. After 48 h of incubation, T cells were analyzed for apoptosis using the FITC annexin V (Anx) Apoptosis Detection Kit I according to manufacturer's protocol (BD Biosciences, Heidelberg, Germany; flow cytometry) (Additional file 5: Figure S5B). Human T cells (Pan T Cell Isolation Kit (human), Miltenyi Biotec) were stimulated (anti-CD3e, 1 µg/mL, Invitrogen, Karlsruhe, Germany) and treated with teri (50 or 100 µM) with or without FTC (10 µM), and T cells were analyzed for apoptosis after 72 h as described above (Additional file 5: Figure S5B).

Measurement of teri concentration by HPLC and LC-MS/MS

For teri plasma and tissue concentration, blood and respective organs were collected from PBS-perfused animals after teri-treatment (MOG_{35–55}-immunized or non-immunized, 17–20 days after initiation of therapy). Blood was collected by cardiac puncture and plasma was stored at – 80 °C. For teri tissue concentration, the liver, spleen, brain, and spinal cord were frozen in liquid nitrogen and stored at – 80 °C. For intracellular concentrations after in vitro teri treatment, collected cells were diluted in acetonitrile (Bisolve, Valkenswaard, Netherlands) and subsequently lysed using ultrasound. High-performance liquid chromatography (HPLC)

followed by liquid chromatography-mass spectrometry (LC-MS/MS) was performed as described previously [19].

Quantitative real-time PCR analyses

For quantitative real-time PCR (qRT-PCR), healthy animals (Ctrl.) or animals during the acute (16 or 18 days after immunization) or chronic (26 days after immunization) phase were perfused with PBS. The spleen, isolated T cells from the spleen diluted in RLT buffer (Qiagen, Germany), spinal cord tissue, and liver were frozen in liquid nitrogen and stored at – 80 °C. Microvessels from the spinal cord and brain were isolated as previously described [20]. RNA was isolated using TRIZOL followed by the RNAeasy Kit Mini (Qiagen, Germany) and transcribed to cDNA according to the manufacturer's protocol (Super Mix; Quanta Biosciences, USA). QRT-PCR was performed on an ABI real-time PCR system (Applied Biosystems, Darmstadt, Germany) using PerfeCTa FastMixII master mix (Quanta Bioscience) and *abcg2*-primer (5'→3' sense-GCA CCT CAA CCT GCC CAT T; antisense-TCA GGG TGC CCA TCA CAA C; FAM-CAT CTT GAA CCA CAT AAC CTG AAC AGC ATT TG; Microsynth, Baldgach, Switzerland), normalized to the housekeeping gene β -actin (primer: Mm00607939_s1 Actb, Applied Biosystems) using the $\Delta\Delta$ ct method.

Statistical methods


Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc., San Diego, USA). Data is presented as mean \pm standard error of the mean (SEM). Statistical tests performed are indicated in the figure legends. Probability level (*p* value) is indicated as **p* < 0.05, ***p* < 0.01, and ****p* < 0.001.

Results

abcg2-deficiency or pharmacological inhibition increases teriflunomide effects in splenic T cells

We first investigated whether *abcg2* activity determines intracellular teri concentrations. Intracellular teri concentration in splenic T cells from *abcg2*-KO mice was 2.5-fold higher than in T cells from wt animals (*p* < 0.05; Fig. 1a).

To further investigate whether reduced *abcg2* activity and increased intracellular teri concentration are associated with functional effects, we analyzed teri-induced inhibition of proliferation as well as apoptosis in splenic CD3⁺ T cells. Increased teri-induced inhibition of T cell proliferation was observed in cells from *abcg2*-KO mice (12.5–100 µM teri, *p* < 0.05; Fig. 1b). Likewise, pharmacological *abcg2* inhibition in T cells from wt mice led to an increase of teri-induced apoptosis (Ko143 vs. DMSO: 3.1-fold, *p* < 0.05; FTC vs. DMSO: 2.8-fold, *p* > 0.05; Fig. 1c). In contrast, apoptosis was not increased in human T cells



after ABCG2 inhibition (Δ apoptosis, DMSO = 4.8 %; FTC = 5.9%; Wilcoxon test, $p > 0.05$; $n = 5$).


We further evaluated potential immunomodulatory effects of teri on T cell responses in vitro. However, neither in the percentage fractions of CD4⁺CD45⁺ and CD8⁺CD45⁺ T cells nor in the cytokine production (IFN- γ , IL-17, GM-CSF, IL-2, IL-10) relevant differences between genotypes were observed. Only secretion of IL-17 was increased in *abcg2*-KO cells compared to wt cells, however, without differences compared to respective teri-treated cells (Additional file 1: Figure S1).

***abcg2*-deficiency increases the therapeutic response to teriflunomide in experimental autoimmune encephalomyelitis**

Next, we investigated whether *abcg2*-mRNA expression is regulated during different phases of EAE in wt mice. Within the spinal cord, *abcg2*-mRNA expression levels decreased during the acute phase (d16 or d18 after immunization; Ctrl. vs. acute: fivefold, $p > 0.05$; Additional file 2: Figure S2A) but increased during the chronic phase (d26 after immunization; Ctrl. vs. acute: twofold, $p > 0.05$; Additional file 2: Figure S2A). Pilot data indicates reduced *abcg2*-expression during the acute phase in microvessels isolated from the spinal cord (Ctrl. vs. acute: threefold, $p < 0.05$, $n = 4$ –5, MWU test) but not in brain microvessels ($p > 0.05$, $n = 2$ –4, MWU test). In peripheral organs, *abcg2*-expression was significantly decreased in splenic T cells in the acute phase (fivefold, $p < 0.05$; Additional file 2: Figure S2C) but not during the chronic phase. *abcg2*-mRNA expression was also

reduced in the liver during the chronic phase (twofold, $p < 0.05$; Additional file 2: Figure S2B).

We next investigated whether *abcg2* has a functional impact on the therapeutic effects of teri. Teri (10 mg/kg body weight) administered therapeutically after individual disease onset of each animal (score > 1) was not efficacious in wt animals as compared to respective sham-treated controls (mean cumulative EAE score \pm SEM; wt teri 5.1 ± 0.3 ; wt vehicle 4.9 ± 0.3 ; Fig. 2a). In contrast, using this teri dose, EAE disease course of *abcg2*-KO mice was strongly ameliorated (*abcg2*-KO teri 3.9 ± 0.2 ; *abcg2*-KO vehicle 4.6 ± 0.3 ; Fig. 2a). Teri concentration within the spinal cord was significantly increased in *abcg2*-KO mice after treatment (*abcg2*-KO teri vs. wt teri, $p < 0.05$; Fig. 2b). Pilot data further indicate higher teri concentration at similar CD3⁺ T cell numbers in *abcg2*-KO mice in comparison to respective wt animals (0–199 CD3⁺ cells/mm²: *abcg2*-KO = 277 ± 186.3 ng/mL, wt = 7.5 ± 7.5 ng/mL; 200–599 CD3⁺ cells/mm²: *abcg2*-KO = 2207 ± 1211 ng/mL, wt = 727.5 ± 336.8 ng/mL; mean \pm SEM; $n = 2$ –3; $p > 0.05$, MWU test). In contrast, teri concentrations in the plasma (*abcg2*-KO teri 71656 ± 8553 ng/ml; wt teri 68472 ± 8300 ng/ml; mean \pm SEM, $n = 7$ –10, $p > 0.05$, Fig. 2c), spleen (*abcg2*-KO teri 3155 ± 473 ng/g; wt teri 5514 ± 1077 ng/g; mean \pm SEM; $n = 7$ –8, $p > 0.05$, MWU test), liver (*abcg2*-KO teri 35008 ± 3428 ng/g; wt teri $37,857 \pm 3010$ ng/g; mean \pm SEM; $n = 6$ –7, $p > 0.05$, MWU test), and brain (*abcg2*-KO teri 453 ± 95 ng/g; wt teri 495 ± 123 ng/g; mean \pm SEM; $n = 9$ –10, $p > 0.05$, MWU test)



did not show significant differences between *abcg2*-KO mice and wt animals. In non-immunized control animals treated with 10 mg/kg teri for 20 consecutive days, teri concentrations in the spinal cord and plasma were similar (spinal cord, *abcg2*-KO teri = 442 ± 160 ng/g; wt teri = 621 ± 280 ng/g; mean \pm SEM, $n = 3$, $p > 0.999$, MWU test and plasma, *abcg2*-KO teri = $63,949 \pm 16,544$ ng/mL; wt teri = $82,766 \pm 7553$ ng/mL; mean \pm SEM; $n = 3$, $p > 0.999$, MWU test). Lower teri dosages (5 mg/kg and 7.5 mg/kg) did not show beneficial effects on EAE disease course in wt or in *abcg2*-KO mice (data not shown).

Treatment effects of teri on EAE disease course were corroborated histologically by 2.4-fold reduced demyelination of spinal cord tissue in teri-treated *abcg2*-KO mice ($p < 0.05$) whereas teri-treated wt animals did not exhibit a significant difference in comparison to respective sham-treated controls (Fig. 2d, e). During the chronic disease phase, the inflammatory score or number of infiltrating CD3⁺ T cells, Mac3⁺ macrophages, and B220⁺ B cells in the spinal cord did not show statistically significant differences of teri-treated mice compared to vehicle-treated mice within both genotypes; however,

observations tended to be consistent with the clinical scores (Additional file 3: Figure S3A–E).

At the peak of EAE (day 4 ± 1 after individual disease onset), peripheral T cell subsets (CD4⁺CD45⁺ T cells, CD8⁺CD45⁺ T cells, and CD4⁺CD25⁺FoxP3⁺ T cells; spleen and inguinal lymph nodes) and cytokine production of T cells (IFN-γ, IL-17, GM-CSF, IL-4, and IL-10) were similar in *abcg2*-KO and wt mice treated with 10 mg/kg teri or vehicle (Additional file 4: Figure S4).

Discussion

Here, we identify ABCG2 as a determinant of teri-induced effects in a murine model of MS. Increased intracellular teri concentration in T cells lacking *abcg2* indicates that teri is a substrate for active cellular drug efflux in this model. Functional relevance of *abcg2*-deficiency and pharmacological inhibition was shown by increased teri-induced cellular effects on proliferation and apoptosis. In EAE, *abcg2*-mRNA is differentially expressed during the acute and chronic disease stages and in different potential target tissues and cells, and *abcg2*-deficiency leads to increased therapeutic effects accompanied by an increased teri concentration within the spinal cord.

Teri concentrations used in our in vitro experiments were matched to steady-state plasma concentrations of 20–60 mg/L (equivalent to approximately 100–300 μM) reached in humans treated with the approved dose of 7 or 14 mg/day [21]. Intracellular teri concentration was more than twofold higher in *abcg2*-deficient T cells after short incubation time of 2–6 h. Pharmacological inhibition of *abcg2* led to an increase of teri-induced apoptosis in murine T cells at the highest teri concentration (100 μM). Using the same concentration, no cytotoxic effects were detected in human lymphocytes, which is in line with previous data [18].

Rodent and human ABCG2 is expressed in most CNS cells with highest expression at physiological barriers like the BBB or blood-spinal-cord barrier [5, 22, 23]. Due to its function at physiological barriers, *abcg2* influences the pharmacokinetics of pharmaceutical drugs [1]. This is also likely for teri for which a significant amount was found to be excreted into milk (> 23%) in lactating rats [24] which corresponds to well-known functions of *abcg2* contributing to the accumulation of drugs in milk shown in mice [25]. However, although the summary of product characteristics states that teri is a substrate of ABCG2 [7], detailed human data are lacking. Our data indicate that intracellular and tissue levels rather than mere plasma levels are likely to be of relevance. Endogenous substrates of ABC transporters include chemokines and cytokines, suggesting a potential contribution to neuroinflammation and degeneration. Alterations of ABC-transporter activity were demonstrated in

active MS-lesions [26]. In addition to inflammatory and oxidative stress [22], apolipoprotein E was also shown to regulate transporter abundance and localization at the BBB in an experimental stroke model [20]. In peripheral organs, reduced *abcg2*-expression during the chronic phase of EAE was observed in splenic T cells. Also, liver *abcg2*-expression was reduced during EAE, whereas teri plasma levels were not different between genotypes. Our data also indicates that *abcg2*-deficiency alone does not change systemic CNS steady-state teri concentrations which are reached after repeated teri doses in mice after approximately 1 month [24]. Hypothetically, *abcg2*-expression by microvessels and infiltrating (T) cells regulated during EAE may have an impact on teri concentration within the autoimmune inflamed spinal cord. Taken together with our in vitro results, we also hypothesize on *abcg2*-dependent effects on teri efficacy occurring during peripheral T cell proliferation. However, to elucidate the exact site(s) of action of teri and additional impact of *abcg2*, further experiments including conditional and chimeric animal models are needed as well as experiments on potential functional redundancy. Furthermore, *abcg2*-dependent effects on pleiotropic mechanisms of action of teri (i.e., T cell mitochondrial respiration [11];) with emphasis on teri concentrations within cell organelles would be interesting to investigate. However, these aspects were beyond the scope of the current study which set out to investigate if *abcg2* has an effect on teri-treatment in vivo.

Our findings support a functional relevance of *abcg2* in vivo, since a suboptimal teri dosage without clinical effect in wt animals strongly ameliorated the EAE disease course in *abcg2*-KO mice, corroborated by reduced spinal cord demyelination. In addition to mere tissue teri concentrations altered drug kinetics may be relevant. However, whether plasma concentrations in *abcg2*-KO mice increase more rapidly than in wt mice remains to be determined and also tissue concentrations may behave differently. Teri shows strain- and species-dependent differences with higher dosages required for effects on EAE disease onset and/or severity in mice (10 mg/kg/day) than in rats (3–10 mg/kg/day) [13, 14]. In the MOG-induced C57BL/6 EAE model, 10 mg/kg teri administered prophylactically (i.e., before onset of signs) prevents disease occurrence [14]. In MOG_{35–55} EAE in C57BL/6 wt mice, teri has no effect in a therapeutic setting (i.e., after onset of signs) at tolerable concentrations (teriflunomide Investigator Brochure 2019, internal Sanofi data). In order to address our hypothesis of increased teri effects in *abcg2*-deficient mice, the well-tolerated teri dose which is prophylactically efficacious in MOG-EAE (10 mg/kg, starting on day 3 after immunization [14];) was used in our setting with a therapeutic teri administration after onset of signs.

Finally, the dosage used in our experiments is comparable to the human situation with steady-state plasma concentrations in wt mice ($68 \pm 83 \mu\text{g/mL}$) comparable to the steady-state plasma concentrations in humans undergoing therapy with *teri* with the approved dosages of 7 or 14 mg ($20\text{--}60 \mu\text{g/mL}$) [21].

Different studies suggest that *teri* has a significant influence on the inflammatory response of various immune cells including reduction of proinflammatory cytokines and modulation of innate immune functions associated with decreased neurotoxicity (e.g., [27, 28]). Our data indicates that in the animal model, therapeutic modulation of *teri* efficacy in *abcg2*-KO mice is not associated with a modulation of peripheral T cell populations. In MS patients treated with *teri* and in rodents suffering from EAE treated with the respective prodrug leflunomide, it was demonstrated that different T cell populations were selectively affected with a preferential reduction in Th1 effector cells [11]. The differences observed may be explained by different drugs, treatment duration, or therapeutic setting.

Single nucleotide polymorphisms (SNP) in the *ABCG2* gene can alter protein expression and activity [1]. Both *ABCB1* and *ABCG2* genes are highly polymorphic with a high frequency of functionally relevant variant alleles in different MS populations [5]. Functional relevance for MS treatment was demonstrated with the well-characterized *ABCG2* substrate mitoxantrone. In retrospective analyses, association of SNPs in *ABCB1* and *ABCG2* genes with drug effects has been shown at least for relapsing and secondary progressive MS [5] but not for primary progressive MS [29]. During treatment with leflunomide, oral clearance of its active metabolite *teri* was associated with *ABCG2* SNPs [21].

Conclusion

Since ABC transporters are highly conserved between rodents and humans [30], our study which demonstrates an impact of *abcg2* on *teri*-treatment in the animal model of MS argues for further investigations on functional relevance of *abcg2*-modulation on specific substrates such as *teri*. Thus far, pharmacological inhibition of respective ABC-transporters as a therapeutic approach has been unsuccessful despite several efforts especially in oncology [2]. Therefore, further investigation of pharmacogenomic association of *ABCG2*, spatiotemporal regulation under the influence of different drugs, potential redundancy, and functional consequences are needed to substantiate the biologically plausible claim that ABC transporters and their modulation may impact individual treatment responses.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12974-019-1677-z>.

Additional file 1: Figure S1. Cytokine expression of splenic $\text{CD4}^+\text{CD45}^+$ and $\text{CD8}^+\text{CD45}^+$ T cells after in vitro stimulation with *teri*. Splenocytes from *abcg2*-KO and wt mice were treated with *teri* ($100 \mu\text{M}$; 2 h) and assessed for cytokine expression by flow cytometry. (A) Gating strategy to identify $\text{CD4}^+\text{CD45}^+$ and $\text{CD8}^+\text{CD45}^+$ T cells. (B) Percentage fraction of $\text{CD4}^+\text{CD45}^+$ and $\text{CD8}^+\text{CD45}^+$ cells. Cytokine expression of CD4^+ T cells (C) and of CD8^+ T cells (D). Cells isolated from $n=6$ mice per genotype were divided in 2 treatment groups (DMSO and $100 \mu\text{M}$ *teri*). Two-Way ANOVA (Turkey's multiple comparison test): * $p<0.05$; ** $p<0.01$; *** $p<0.001$. wt: C57BL/6J wild type mice; *abcg2*-KO: *abcg2*-deficient mice on C57BL/6J background; *teri*: teriflunomide.

Additional file 2: Figure S2. Differential *abcg2*-expression during experimental autoimmune encephalomyelitis. Relative *abcg2*-mRNA (quantification by TaqMan PCR using $\Delta\Delta\text{Ct}$ method; normalized to β -actin) during the acute or chronic phase of MOG_{35-55} EAE in female C57BL/6J wild type mice compared to healthy controls. (A) spinal cord, Kruskal-Wallis test; (B) liver, MWU-test; (C) splenic T cells, Kruskal-Wallis test; (D) spleen, MWU-test. Ctrl: healthy control; ac EAE: acute phase of EAE (d16/18 after immunization); chr EAE: chronic phase of EAE (d26 after immunization); statistics: * $p<0.05$; ** $p<0.01$.

Additional file 3: Figure S3. Histopathological characterization of spinal cords of *abcg2*-KO and wt mice after *teri*-treatment (10 mg/kg body weight, 17-20 days) during active MOG_{35-55} EAE. (A) Inflammatory score of spinal cord lesions (H&E staining); evaluated as inflammatory score as described in the methods, obtained at two sections of spinal cord tissue per each mouse. (B) Representative pictures of H&E staining ($40\times$ magnification, scale bar $20 \mu\text{m}$). Quantification of (C) CD3^+ cells (T-cells), (D) Mac3^+ cells (macrophages) and (E) B220^+ cells (B-cells); evaluated as cells/ mm^2 , obtained at two sections of spinal cord tissue per each mouse. A-D: $n=6-13$; MWU-test, $p=\text{ns}$. wt: C57BL/6J wild type mice; *abcg2*-KO: *abcg2*-deficient mice on C57BL/6J background; *teri*: teriflunomide.

Additional file 4: Figure S4. Immunomodulation of T cell responses after *teri*-treatment during MOG_{35-55} EAE: Cytokine expression $\text{CD4}^+\text{CD45}^+$ and $\text{CD8}^+\text{CD45}^+$ T cells from spleen (A-D) and inguinal lymphnodes (E-H) and percentage of $\text{CD25}^+\text{FoxP3}^+$ of CD4^+ T cells from spleen and inguinal lymphnodes (I-J). *Teri*-treatment (10 mg/kg) of active MOG_{35-55} EAE, once daily p.o. (4 ± 1 days), individually after disease onset (Score >1) in *abcg2*-KO and wt mice. (A, E) Gating strategy to identify $\text{CD4}^+\text{CD45}^+$ and $\text{CD8}^+\text{CD45}^+$ T cells. (B, F) Percentage fraction of $\text{CD4}^+\text{CD45}^+$ and $\text{CD8}^+\text{CD45}^+$ cells. Cytokine expression of CD4^+ T cells (C, G) and of CD8^+ T cells (D, H). (I) Gating strategy to identify $\text{CD25}^+\text{FoxP3}^+$ cells of CD4^+ cells. (J) Percentage portion of $\text{CD4}^+\text{CD25}^+\text{FoxP3}^+$ cells. Data were assessed by flow cytometry. Two-Way ANOVA (Turkey's multiple comparison test): * $p<0.05$; ** $p<0.01$. wt: C57BL/6J wild type mice; *abcg2*-KO: *abcg2*-deficient mice on C57BL/6J background; *teri*: teriflunomide; LN: inguinal lymphnodes.

Additional file 5: Figure S5. Gating strategies of proliferation and apoptosis assays (see Fig. 1). (A) Gating strategy to identify the fraction of proliferating CFSE $^+$ PI $^+$ T cells. Representative figures of wt T cells treated with DMSO or *teri* ($100 \mu\text{M}$ *teri*) for 48 h. Proliferation index was calculated as follows: normalized to \emptyset cell death ($= \frac{\% \text{Proliferation}}{\% \text{Proliferation (vehicle)}} \times \frac{(100 - \emptyset \text{cell death})}{100}$); quotient vehicle-treated cells to *teri*-treated cells ($= \frac{\% \text{proliferation (vehicle)}}{\% \text{proliferation (teri)}} \times (-1)$). (B) Gating strategy of apoptosis to identify percentage fraction of apoptotic T cells. Representative pictures of wt cells treated with DMSO for 48 h. Apoptosis was calculated as sum of Anx^+ , AnxPI^+ and PI^+ T cells.

Additional file 6: Table S1. Flow cytometry antibodies.

Abbreviations

ABC: Adenosine triphosphate-binding cassette; Anx: Annexin V; BBB: Blood-brain barrier; CFSE: Carboxy-fluorescein-diacetate-succinimideylester; CNS: Central nervous system; Ctr: Control (i.e., healthy or non-immunized mice); DHODH: Dihydro-orotate dehydrogenase; EAE: Experimental autoimmune encephalomyelitis; FTC: Fumitremorgin C; GM-CSF: Granulocyte

macrophage colony-stimulating factor; H&E: Hematoxylin and eosin; HPLC: High-performance liquid chromatography; IFN- γ : Interferon gamma; KO: Knockout; LFB: Luxol fast blue; LS-MS/MS: liquid chromatography-mass spectrometry; MOG: Myelin-oligodendrocyte-glycoprotein; MS: Multiple sclerosis; PBMC: Peripheral blood mononuclear cells; PI: Propidium iodide; qRT-PCR: Quantitative real-time PCR; SNP: Single nucleotide polymorphism; Teri: Teriflunomide

Acknowledgements

We thank Dr. S. Goelz and Prof. R. Gold for the critical discussions as well as K. Thuss-Silczak, F. Arakrak, and V. Bösigler for expert technical assistance and M. Schlimm for conduction of pilot experiments for *abcg2*-expression in the spinal cord and brain microvessels.

Authors' contributions

LT, AC contributed to the study concept and design of experiments and wrote the paper. LT, KG, ST, JR, XP, and MP contributed to the performance of experiments. LT, RH, ST, SD, AS, TT, and SW contributed to the analysis and interpretation of the data. DMH, BE, FL, and AC contributed reagents/materials/analysis tools. KG, ST, RH, AS, TT, BE, DMH, FL, SW, and AC contributed to the revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding

Sanofi Genzyme supported the investigator-initiated preclinical study by an unrestricted grant. This does not alter our adherence to the Journal of Neuroinflammation policies on sharing data and materials.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics approval

All experiments were reviewed and approved by the Veterinary Office of the Canton of Bern (permission number: BE 64/16) or the North Rhine-Westphalia authorities for animal experimentation (permission number: 84-02.04.2015.A006). Human studies were approved by the local cantonal ethic committee Bern (KEK-BE 2017-00060).

Consent for publication

Not applicable

Competing interests

LT received speaker honoraria and travel support from Sanofi Genzyme. KG is a former employee of Biogen, not related to this work. ST reports no competing interests. JR, XP, MP, FL, and SW report no disclosures. SD received compensation for activities with Sanofi Genzyme. RH received research and travel grants from Novartis and Biogen Idec. He also received speaker's honoraria from Biogen, Novartis, Merck and Almirall. AS received speaker honoraria and/or travel compensation for activities with Almirall Hermal GmbH, Biogen, Merck, Novartis, Roche and Sanofi Genzyme, not related to this work. TT is an employee of Sanofi. BE received funding for a research project not related to this work. DMH reports no competing interests. He has received funding from the Deutsche Forschungsgemeinschaft (HE3173/2-2). AC has received compensation for activities with Actelion, Almirall, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, and Teva, all for university research funds. He has served as country principle investigator for teriflunomide phase III trials in Germany. He receives research support from the Swiss National Science Foundation, Biogen, Genzyme, and UCB. He serves in the editorial board for Clinical and Translational Neuroscience and the Journal of International Medical Research.

Author details

¹Department of Neurology, Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Freiburgstrasse, 3010 Bern, Switzerland. ²Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44801 Bochum, Germany. ³Sanofi, Cambridge, MA 02142, USA. ⁴Theodor Kocher Institute, University of Bern, Bern, Switzerland. ⁵Department of Neurology, University of Duisburg-Essen, 45147 Essen, Germany. ⁶Institute for Neuroimmunology and Multiple Sclerosis Research, University Medical Center Göttingen, 37075 Göttingen, Germany. ⁷Group for

Cell Morphology and Molecular Neurobiology, Group of Molecular Cell Biology, Ruhr-University Bochum, 44801 Bochum, Germany.

Received: 14 June 2019 Accepted: 16 December 2019

Published online: 08 January 2020

References

- Heyes N, Kapoor P, Kerr ID. Polymorphisms of the Multidrug Pump ABCG2: A systematic review of their effect on protein expression, function, and drug pharmacokinetics. *Drug Metab Dispos.* 2018;46:1886–99.
- Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat Rev Cancer.* 2018;18:452–64.
- Manolaridis I, Jackson SM, Taylor NMI, Kowal J, Stahlberg H, Locher KP. Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states. *Nature.* 2018;563:426–30.
- Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhelyi O, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. *Ann Rheum Dis.* 2009;68:1201–7.
- Cotte S, Von Ahnen N, Kruse N, Huber B, Winkelmann A, Zettl UK, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. *Brain.* 2009;132:2517–30.
- Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafò A. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. *Clin Pharmacokinet.* 2018; Available from: <https://doi.org/10.1007/s40262-018-0695-9>.
- European Medicines Agency. Summary of Product Characteristics (last updated 27/03/2019) [Internet]. 2013. Available from: https://www.ema.europa.eu/en/documents/product-information/abagio-epar-product-information_en.pdf
- Coyle PK. Pharmacogenetic biomarkers to predict treatment response in multiple sclerosis: current and future perspectives. *Mult Scler Int.* 2017; 2017:1–10.
- Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. *Nat Rev Neurol.* 2018; Available from: <http://www.nature.com/articles/s41582-018-0082-z>.
- Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. *Ther Adv Neurol Disord.* 2017;10:381–96.
- Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, et al. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. *Sci Transl Med.* 2019;11 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/31043571>.
- Hoepner R, Bagnoud M, Pistor M, Salmen A, Briner M, Synn H, et al. Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. *Acta Neuropathol.* Springer Berlin Heidelberg; 2019; Available from: <https://doi.org/10.1007/s00401-019-02018-8>
- Merrill JE. In vitro and in vivo pharmacological models to assess demyelination and remyelination. *Neuropsychopharmacol Rev.* 2009; 34145:55–73.
- Redaelli C, Gaffarogullari EC, Brune M, Pilz C, Becker S, Sonner J, et al. Toxicity of teriflunomide in aryl hydrocarbon receptor deficient mice. *Biochem Pharmacol.* 2015;98:484–92.
- Seno A, Maruhashi T, Kaifu T, Yabe R, Fujikado N, Ma G, et al. Exacerbation of experimental autoimmune encephalomyelitis in mice deficient for DCIR, an inhibitory C-type lectin receptor. *Exp Anim.* 2015;64:109–19.
- Tietz S, Périnat T, Greene G, Enzmann G, Deutsch U, Adams R, et al. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis. *Brain Behav Immun.* 2018;73:3–20 Available from: <https://doi.org/10.1016/j.bbi.2018.06.014>.
- Harding FA, McArthur JG, Gross JA, Raulat DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. *Nature.* 1992;356:607–9.
- Li L, Liu J, Delohery T, Zhang D, Arendt C, Jones C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. *J Neuroimmunol.* 2013;265:82–90.
- Filali-Ansary A, Lunven C, Turpault S, Beyer Y-J, O'Brien A, Delfolie A, et al. Dried blood spot methodology in combination with liquid chromatography/tandem mass spectrometry facilitates the monitoring of teriflunomide. *Ther Drug Monit.* 2016;38:471–82.

20. Elali A, Urrutia A, Rubio-Araiz A, Hernandez-Jimenez M, Colado MI, Doepfner TR, et al. Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters ABCB1 and ABCC1 on cerebral microvessels after methamphetamine intoxication. *Stroke*. 2012;43:1647–53.
21. Wiese MD, Rowland A, Polasek TM, Sorich MJ, O'Doherty C. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. *Expert Opin Drug Metab Toxicol*. 2013;9:1025–35.
22. Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. *Brain Res*. 2015; 1628:298–316.
23. Campos CR, Schröter C, Wang X, Miller DS. ABC transporter function and regulation at the blood-spinal cord barrier. *J Cereb Blood Flow Metab*. 2012;32:1559–66 Available from: <http://journals.sagepub.com/doi/10.1038/jcbfm.2012.47>.
24. European Medicines Agency. Aubagio: EPAR- Public assessment report. 2013. Available from: https://www.ema.europa.eu/en/documents/assessment-report/aubagio-epar-public-assessment-report_en.pdf
25. Jonker JW, Merino G, Musters S, Van Herwaarden AE, Bolscher E, Wagenaar E, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. *Nat Med*. 2005;11:127–9.
26. Kooij G, Van Horsen J, Bandaru VVR, Haughey NJ, De Vries HE. The role of ATP-binding cassette transporters in neuro-inflammation: relevance for bioactive lipids. *Front Pharmacol*. 2012;3:1–6.
27. Wostradowski T, Prajeeth CK, Gudi V, Kronenberg J, Witte S, Brieskorn M, et al. In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia. *J Neuroinflammation*. 2016;13:250.
28. Ambrosius B, Faissner S, Guse K, von Lehe M, Grunwald T, Gold R, et al. Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity. *J Neuroinflammation*. 2017;14:1–10.
29. Grey Née Cotte S, Salmen Née Stroet A, von Ahsen N, Starck M, Winkelmann A, Zettl UK, et al. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. *J Neuroimmunol*. 2015;278:277–9.
30. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). *Oncogene*. 2003;22:7340–58.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

